CEL-SCI (CVM) Competitors $0.57 -0.04 (-6.10%) (As of 12/4/2024 06:00 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends CVM vs. FTLF, CHRS, ELUT, MCRB, CADL, NBTX, BDTX, IPSC, ADVM, and ABOSShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include FitLife Brands (FTLF), Coherus BioSciences (CHRS), Elutia (ELUT), Seres Therapeutics (MCRB), Candel Therapeutics (CADL), Nanobiotix (NBTX), Black Diamond Therapeutics (BDTX), Century Therapeutics (IPSC), Adverum Biotechnologies (ADVM), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. FitLife Brands Coherus BioSciences Elutia Seres Therapeutics Candel Therapeutics Nanobiotix Black Diamond Therapeutics Century Therapeutics Adverum Biotechnologies Acumen Pharmaceuticals CEL-SCI (NYSE:CVM) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk. Is CVM or FTLF more profitable? FitLife Brands has a net margin of 13.38% compared to CEL-SCI's net margin of 0.00%. FitLife Brands' return on equity of 28.03% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -239.31% -102.69% FitLife Brands 13.38%28.03%15.13% Do analysts rate CVM or FTLF? FitLife Brands has a consensus price target of $40.00, suggesting a potential upside of 26.94%. Given FitLife Brands' stronger consensus rating and higher probable upside, analysts plainly believe FitLife Brands is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00FitLife Brands 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility & risk, CVM or FTLF? CEL-SCI has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, FitLife Brands has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Does the MarketBeat Community prefer CVM or FTLF? FitLife Brands received 2 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 50.00% of users gave FitLife Brands an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes10100.00% FitLife BrandsOutperform Votes250.00% Underperform Votes250.00% Does the media prefer CVM or FTLF? In the previous week, FitLife Brands' average media sentiment score of 0.43 beat CEL-SCI's score of 0.00 indicating that FitLife Brands is being referred to more favorably in the news media. Company Overall Sentiment CEL-SCI Neutral FitLife Brands Neutral Do insiders & institutionals believe in CVM or FTLF? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 14.1% of CEL-SCI shares are owned by company insiders. Comparatively, 61.3% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, CVM or FTLF? FitLife Brands has higher revenue and earnings than CEL-SCI. CEL-SCI is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$32.19M-$0.58-0.98FitLife Brands$62.76M2.31$5.30M$1.6918.64 SummaryFitLife Brands beats CEL-SCI on 16 of the 17 factors compared between the two stocks. Ad WealthPressIs the Trump/Musk duo good for shares of TSLA?If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$36.37M$3.05B$5.27B$20.22BDividend YieldN/A1.83%5.37%3.43%P/E Ratio-0.9844.68139.4844.69Price / SalesN/A349.071,284.4817.43Price / CashN/A177.0042.1922.41Price / Book2.043.974.805.58Net Income-$32.19M-$41.68M$119.45M$984.96M7 Day Performance-6.71%0.57%3.25%0.02%1 Month Performance-28.75%-0.08%2.64%4.80%1 Year Performance-80.00%35.64%32.43%24.71% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCIN/A$0.57-6.1%N/A-79.6%$38.73MN/A-0.9843FTLFFitLife Brands3.9467 of 5 stars$33.34-1.2%$40.00+20.0%+62.7%$153.30M$62.76M19.9620Short Interest ↑CHRSCoherus BioSciences3.8031 of 5 stars$1.33+9.0%$6.13+360.5%-25.7%$153.23M$257.24M-16.07246Analyst ForecastOptions VolumeGap UpELUTElutia3.266 of 5 stars$4.38+5.8%$10.00+128.3%+104.7%$151.37M$24.75M-1.59180Positive NewsMCRBSeres Therapeutics3.8176 of 5 stars$0.88-10.1%$5.08+476.7%-28.2%$150.49M$126.32M-4.26233CADLCandel Therapeutics2.3539 of 5 stars$4.59-2.5%$11.00+139.7%+392.2%$149.07M$120,000.00-2.7760Gap UpNBTXNanobiotix2.6586 of 5 stars$3.13-3.1%$11.50+267.4%-52.2%$147.53M$36.22M0.00100BDTXBlack Diamond Therapeutics2.8541 of 5 stars$2.57-3.0%$15.50+503.1%+4.2%$145.42MN/A-1.9990Short Interest ↓Positive NewsIPSCCentury Therapeutics2.5608 of 5 stars$1.68-2.3%$11.60+590.5%-10.6%$142.85M$2.68M-0.94170ADVMAdverum Biotechnologies3.7403 of 5 stars$6.86+3.3%$27.83+305.7%-31.9%$142.69M$3.60M-1.11190Positive NewsABOSAcumen Pharmaceuticals1.8871 of 5 stars$2.36+4.0%$9.00+281.4%-16.0%$141.79MN/A-1.6751Positive News Related Companies and Tools Related Companies FitLife Brands Competitors Coherus BioSciences Competitors Elutia Competitors Seres Therapeutics Competitors Candel Therapeutics Competitors Nanobiotix Competitors Black Diamond Therapeutics Competitors Century Therapeutics Competitors Adverum Biotechnologies Competitors Acumen Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CVM) was last updated on 12/5/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
